Literature DB >> 22407354

Is heart rate a treatment target in heart failure?

Jan-Christian Reil1, Michael Böhm.   

Abstract

Clinical and experimental studies confirmed an association between elevated resting heart rate and the risk of mortality in heart failure patients. Importantly, elevated heart rate at rest has been identified as a key finding in heart failure addressing a major treatment target. This review shows that heart rate level at rest and its extent of reduction is a sensitive indicator for successful therapy in heart failure patients demonstrating the specific influence of heart rate reduction on clinical outcome in the analyzed patients. Currently, experimental data provide convincing evidence of a pathophysiological concept of heart rate reduction; nevertheless, transition from experimental results to clinical evidence needs further clarification, especially in patients with diastolic heart failure. Since heart rate can be easily determined during physical examination, decrease in heart rate of patients allows a simple hint on prognosis and efficiency of heart failure therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407354     DOI: 10.1007/s11886-012-0260-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  42 in total

1.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

2.  Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.

Authors:  X Monnet; B Ghaleh; P Colin; O P de Curzon; J F Giudicelli; A Berdeaux
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

3.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).

Authors:  Lars Gullestad; John Wikstrand; Prakash Deedwania; Ake Hjalmarson; Kenneth Egstrup; Uri Elkayam; Stephen Gottlieb; Andrew Rashkow; Hans Wedel; Georgina Bermann; John Kjekshus
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

4.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

5.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

6.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

7.  Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age.

Authors:  A Perski; G Olsson; C Landou; U de Faire; T Theorell; A Hamsten
Journal:  Am Heart J       Date:  1992-03       Impact factor: 4.749

Review 8.  The role of heart rate in the development of cardiovascular disease.

Authors:  J-C Reil; M Böhm
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460

Review 9.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.